DOCSLIB.ORG

MENOPAUSE I Have No Disclosures WHAT’S NEW? WHAT’S SAFE?

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
MENOPAUSE I Have No Disclosures WHAT’S NEW? WHAT’S SAFE? MENOPAUSE I have no disclosures WHAT’S NEW? WHAT’S SAFE? Sara Whetstone, MD, MHS OBJECTIVES •To describe risks of HT by age and menopause onset •To recommend specific HT regimen for women who undergo early menopause and who undergo menopause at the expected time BP is a 52yo woman who HT – Hormone therapy cannot sleep due to her hot flashes. Her last period was ET – Estrogen only therapy approximately 8 months EPT – Estrogen-progestin therapy ago. She is miserable. She GLOSSARY is interested in exploring HT CEE – Conjugated equine estrogen but worried specifically about risks of HT. In the MPA – Medroxyprogesterone acetate past, she has had really bad MP – Micronized progesterone experiences with progestin therapy. TREATMENT OF VASOMOTOR SYMPTOMS Vasomotor symptoms Most effective treatment: systemic hormone therapy (HT) with estrogen therapy INDICATIONS Prevention of bone loss If uterus present... If uterus absent… FOR HT (FDA-APPROVED) Hypoestrogenism (caused by hypogonadism, oophorectomy, or POI) Genitourinary syndrome of Estrogen + Progestin Estrogen alone menopause (GSM) (or vulvo-vaginal atrophy) (EPT) (ET) RISKS AND BENEFITS OF HT IN WOMEN AGES 50-59 OR <10 YEARS OF BENEFITS/RISKS MENOPAUSE OF HT AMONG WOMEN 50-59 Manson JE et al. NEJM, 2016 Santen et al. J Clin Endocrinol Metab. 2010 BP is a 52yo woman who CONTRAINDICATIONS TO SYSTEMIC HT cannot sleep due to her hot flashes. Her last period was .Unexplained vaginal bleeding approximately 8 months .Severe active liver disease ago. She is miserable. She is interested in exploring HT .Estrogen-sensitive breast or endometrial cancer but worried specifically .Coronary heart disease about risks of HT. In the .Stroke past, Whatshe has type had of estrogen really therapy bad do you usually start with? .Personal history or inherited high risk of venous 1)experiences Oral CEE with progestin thromboembolism 2)therapy. Micronized oral 17-beta estradiol 3) Transdermal 17-beta estradiol 4) Oral CEE + bazedoxifene SYSTEMIC TISSUE SELECTIVE ESTROGEN COMPLEX (TSEC) HORMONE THERAPY (HT) FDA approved for Estrogen present to treatment of REGIMENS treat vasomotor vasomotor symptoms symptoms and osteoporosis ACOG Bulletin 141: prevention Management of menopausal CEE/BZA symptoms, 2016. (0.45mg/20mg) SERM to block estrogen action in Progestin is NOT endometrium/uterus needed BZA - Bazedoxifene TABLE 1 Target Tissue TSEC Oral HT (ET and EPT) VMS Improved frequency and severity Improved frequency and severity BP was excited about an Bone Improved BMD Improved BMD, decreased fracture risk option for HT that did not Endometrial Neutral with EPT, increased with ET alone Neutral at 2y neoplasia if uterus present involve a progestin. After Breast cancer Neutral at 2y Increased in WHI trial <1/1000 counseling, BP started 2 fold risk with BZA, no additive 2 fold risk with oral ET & EPT, potentially CEE/BZA with good relief VTE risk risk with CEE/BZA less with transdermal therapies of her vasomotor symptoms. TISSUE EFFECTS OF TSEC VS. TRADITIONAL HT Pinkerton JV et al. Clin Obstet Gynecol, 2018. TG is a 64yo woman who underwent menopause at age 49. JOINT PAIN AND HT She has noticed increased joint .Evidence of estrogen binding to estrogen stiffness and prolonged fatigue receptors on joint tissues after exercising in the last 18 .Inconsistent evidence about effects of ET on months. She was encouraged by osteoarthritis and arthralgia .May be benefits of estrogen and SERMs on joint her PCP to present to GYN to pain discuss initiating hormone . In WHI: replacement therapy for her .Women on CEE + MPA (vs placebo, 47.1% vs symptoms. Her medical history is 38.4%) had less joint pain/stiffness, more discomfort when stopping HT notable for hypertension and .Women on CEE had statistically significant less hyperlipidemia. joint pain (vs placebo, 76.3% vs 79.2%) TG is a 64yo woman who underwent menopause at age 49. She has noticed increased joint stiffness and prolonged fatigue after exercising in the last 18 RISKS OF months. She was encouraged by HT BY AGE her PCP to present to GYN to discuss initiating hormone Would you start replacement therapy for her TG on HT? symptoms. Her medical history is 1) Yes notable for hypertension and 2) No hyperlipidemia. 3) Maybe Manson JE, JAMA 2013. Potential risk Age and/or time from menopause onset <60 years or <10 years from >10 years from menopause menopause Coronary heart Potential for increased risk NAMS ALGORITHM Reduced risk of CHD disease of CHD All-cause Significant reduction in all-cause No protective effect of HT mortality mortality Meta-analysis of RCTs: No Meta-analysis of RCTs: Stroke increased risk of stroke Increased risk of stroke Observational studies: mixed Rare risk but significantly VTE Higher absolute risk increased with HT SUMMARY OF HEALTH RISKS OF HT BY AGE AND/OR TIME FROM MENOPAUSE ONSET Manson JE, Menopause, 2015. “For women who initiate HT more than 10 to 20 years from menopause onset or when aged 60 years or older, the benefit-risk ratio appears less favorable than for younger women because of CVD RISK AND greater absolute risks of CHD, TIME SINCE stroke, VTE, and dementia.” MENOPAUSE ONSET 2017 HT Position Statement of NAMS PB is 66yo G0 woman who underwent bilateral CONSEQUENCES OF EARLY MENOPAUSE AND oophorectomy at age 40 after PRIMARY OVARIAN INSUFFICIENCY her sister was diagnosed with ovarian cancer. She was started on HRT for very bothersome hot flashes. She Vasomotor Bone loss and Increased heart symptoms GSM osteoporosis disease presents to discuss continuation of HRT. She is currently taking PO conjugated equine estrogen Dementia and Depression and Higher overall (CEE) and continuous cognitive anxiety related decline disorders mortality medroxyprogesterone acetate (MPA). Vasomotor symptoms MANAGEMENT OF EARLY MENOPAUSE Hormone replacement INDICATIONS Prevention of bone loss Estrogen therapy Exercise • Dosage higher than usual FOR HT post-menopausal ET (FDA-APPROVED) Healthy diet Hypoestrogenism • Monitoring estradiol levels (caused by hypogonadism, oophorectomy, or POI) Adequate calcium and NOT recommended vitamin D intake Progestin necessary if patient Genitourinary syndrome of Avoidance of smoking has intact uterus menopause (GSM) (or vulvo-vaginal atrophy) PB is 66yo G0 woman who underwent bilateral oophorectomy at age 40 after her sister was diagnosed with ovarian cancer. She was started on HRT for very bothersome hot flashes. She presents to discuss continuation of HRT. She is currently taking PO conjugated equine estrogen (CEE) and continuous medroxyprogesterone acetate RECOMMENDED TREATMENTS ACOG Committee Opinion, 2017. (MPA). COMMON HT Estrogen replacement (E+P) REGIMENS • Transdermal recommended (over oral) • Can also use vaginal ET • Lower risk of VTE • Rovinski D (2018): Oral HT was CHOOSING associated with increased risk of WHICH REGIMEN VTE, while non-oral HT was not • Lower risk of stroke TO PRESCRIBE • Lower risk of hypertriglyceridemia Bottom Line: Start with transdermal estrogen patch (17-beta estradiol) BREAST & CV EFFECTS OF PROGESTINS Progestin therapy Recommendation for oral micronized progesterone (MP) CHOOSING Sequential: 200mg/day x 12 WHICH REGIMEN days per month Continuous: 100mg daily TO PRESCRIBE Llaneza P, Gynecol Endocrinol, 2018. Disadvantages Using LNG-IUS for endometrial (1) Higher dose of E+P protection would be considered an off- therapy label use (2) ?inferior to higher dose HT in regards to BMD Reasonable to consider in women who do not tolerate oral progestins WHAT ABOUT WHAT ABOUT LEVONORGESTEREL Can be utilized by women who desire IUD? ET at non-contraceptive levels and who OCPS? are still at risk of pregnancy Advantages Effective for endometrial protection for peri-menopausal and post-menopausal (1) Easier to use, less stigma women using ET (2) Offers contraception PB is 66yo G0 woman who Should PB stop HT? underwent bilateral 1) Yes WHEN TO STOP HORMONE REPLACEMENT? oophorectomy at age 40 after 2) No her sister was diagnosed with ovarian cancer. She was 3) It depends… .Treatment for women with primary ovarian insufficiency/early started on HRT for very menopause should continue until the average age of natural bothersome hot flashes. She menopause (50–51 years) presents to discuss continuation .Treatment may continue past age 50–51 years if a woman has of HRT. She is currently taking clinical symptoms or indications. PO conjugated equine estrogen .Regardless of age, the decision to continue HT should be (CEE) and continuous individualized and based on a woman’s symptoms and the risk– medroxyprogesterone acetate benefit ratio. (MPA). WHEN TO STOP? Extended use may benefit women for relief of VMS, prevention of bone loss and fracture, and treatment/prevention of GSM DURATION OF Vasomotor symptoms recur in 50% of women Many of the benefits/risks of HT do not persist beyond 5 to 7 years TREATMENT Elevated (but rare absolute risk) of breast cancer with CEE + MPA in median 13 yr follow-up CVD risk became neural Bone protection rapidly dissipates after HT discontinuation Significant reduction in breast cancer with CEE during 13 year follow-up All-cause mortality was neutral in CEE + MPA group in 13 year follow-up Data lacking on benefits/risks of longer duration and with discontinuation of HT OUR ADVICE FOR PB: KG is 64yo P2 woman with no significant PMH who presents .Recommend discontinuation of HT for her routine gynecologic visit. She reports dyspareunia .If PB is hesitant to stop HT or has recurrent bothersome menopausal despite lubrication. She symptoms, would recommend declines vaginal estrogen, .Trying non-hormonal treatments .Switching to transdermal estrogen stating “she doesn’t want to try .Switching to micronized any hormonal medications as progesterone she doesn’t perceive them as .Lowering dose as tolerated safe.” .Reassessing HT on an annual basis GENITOURINARY SYMPTOMS AND SYNDROME OF Vulvovaginal MENOPAUSE SIGNS OF GSM atrophy …a collection of signs and symptoms associated with a decrease in estrogen and other sex steroid hormones involving changes to the labia majora/minora, Atrophic vaginitis clitoris, vestibule/introitus, vagina, urethra, and bladder.
Load more

Recommended publications
  • Eraas for Menopause Treatment: Welcome the ‘Designer Estrogens’
    REVIEW CME LEARNING OBJECTIVE: Readers will tailor hormone therapy to the needs of the patient CREDIT HEATHER D. HIRSCH, MD, MS, NCMP ELIM SHIH, MD, NCMP HOLLY L. THACKER, MD, NCMP Assistant Professor, Clinical Internal Medicine, Division Department of Obstetrics and Gynecology, Director of Center for Specialized Women’s Health, of General Internal Medicine, The Ohio State University, Women’s Health Institute, Cleveland Clinic Department of Obstetrics and Gynecology, Women’s Columbus, and Center for Women’s Health, Health Institute, Cleveland Clinic; Professor, Cleveland The Ohio State University Wexner Medical Center, Clinic Lerner College of Medicine of Case Western Upper Arlington, OH Reserve University, Cleveland, OH ERAAs for menopause treatment: Welcome the ‘designer estrogens’ ABSTRACT strogen receptor agonist-antagonists E(ERAAs), previously called selective es- Estrogen receptor agonist-antagonists (ERAAs) selec- trogen receptor modulators (SERMs), have tively inhibit or stimulate estrogen-like action in targeted extended the options for treating the vari- tissues. This review summarizes how ERAAs can be used ous conditions that menopausal women suffer in combination with an estrogen or alone to treat meno- from. These drugs act differently on estrogen pausal symptoms (vasomotor symptoms, genitourinary receptors in different tissues, stimulating re- syndrome of menopause), breast cancer or the risk of ceptors in some tissues but inhibiting them breast cancer, osteopenia, osteoporosis, and other female in others. This allows selective inhibition or midlife concerns. stimulation of estrogen-like action in various target tissues.1 KEY POINTS This article highlights the use of ERAAs Tamoxifen is approved to prevent and treat breast cancer. to treat menopausal vasomotor symptoms It may also have beneficial effects on bone and on car- (eg, hot flashes, night sweats), genitourinary diovascular risk factors, but these are not approved uses.
    [Show full text]
  • Clinical Update on the Use of Ospemifene in the Treatment of Severe Symptomatic Vulvar and Vaginal Atrophy
    Journal name: International Journal of Women’s Health Article Designation: Review Year: 2016 Volume: 8 International Journal of Women’s Health Dovepress Running head verso: Palacios and Cancelo Running head recto: The use of ospemifene in the treatment of severe symptomatic VVA open access to scientific and medical research DOI: http://dx.doi.org/10.2147/IJWH.S110035 Open Access Full Text Article REVIEW Clinical update on the use of ospemifene in the treatment of severe symptomatic vulvar and vaginal atrophy Santiago Palacios1 Abstract: The physiological decrease in vaginal estrogens is accountable for the emergence of María Jesús Cancelo2 vulvar and vaginal atrophy (VVA) and its related symptoms such as vaginal dryness, dyspareunia, vaginal and/or vulvar irritation or itching, and dysuria. The repercussion of these symptoms 1Palacios Institute of Women’s Health, Madrid, Spain; 2Gynecology and on quality of life often makes it necessary to initiate treatment. Up until now, the treatments Obstetrics Department, Guadalajara available included vaginal moisturizers and lubricants, local estrogens, and hormonal therapy. University Hospital, University of Alcalá, Spain However, therapeutic options have now been increased with the approval of 60 mg ospemifene, the first nonhormonal oral treatment with an agonist effect on the vaginal epithelium and an endometrial and breast safety profile which makes it unique. This is the first selective estrogen receptor modulator indicated in women with moderate-to-severe vaginal atrophy not eligible For personal use only. for local estrogen treatment. Considering that “local estrogen noneligible women” are those in whom such treatment cannot be administered either because it is contraindicated or due to skill issues, who are averse to the mode and convenience of vaginal products’ administration or to their use on account of potential systemic absorption, or those who demonstrate dissatisfac- tion in terms of efficacy and safety, it is clear that there is a significant unmet medical need in VVA management.
    [Show full text]
  • Management of Women with Premature Ovarian Insufficiency
    Management of women with premature ovarian insufficiency Guideline of the European Society of Human Reproduction and Embryology POI Guideline Development Group December 2015 1 Disclaimer The European Society of Human Reproduction and Embryology (hereinafter referred to as 'ESHRE') developed the current clinical practice guideline, to provide clinical recommendations to improve the quality of healthcare delivery within the European field of human reproduction and embryology. This guideline represents the views of ESHRE, which were achieved after careful consideration of the scientific evidence available at the time of preparation. In the absence of scientific evidence on certain aspects, a consensus between the relevant ESHRE stakeholders has been obtained. The aim of clinical practice guidelines is to aid healthcare professionals in everyday clinical decisions about appropriate and effective care of their patients. However, adherence to these clinical practice guidelines does not guarantee a successful or specific outcome, nor does it establish a standard of care. Clinical practice guidelines do not override the healthcare professional's clinical judgment in diagnosis and treatment of particular patients. Ultimately, healthcare professionals must make their own clinical decisions on a case-by-case basis, using their clinical judgment, knowledge, and expertise, and taking into account the condition, circumstances, and wishes of the individual patient, in consultation with that patient and/or the guardian or carer. ESHRE makes no warranty, express or implied, regarding the clinical practice guidelines and specifically excludes any warranties of merchantability and fitness for a particular use or purpose. ESHRE shall not be liable for direct, indirect, special, incidental, or consequential damages related to the use of the information contained herein.
    [Show full text]
  • CP.PMN.168 Ospemifene (Osphena)
    Clinical Policy: Ospemifene (Osphena) Reference Number: CP.PMN.168 Effective Date: 08.28.18 Last Review Date: 11.20 Line of Business: Commercial, HIM, Medicaid Revision Log See Important Reminder at the end of this policy for important regulatory and legal information. Description Ospemifene (Osphena®) is a selective estrogen receptor modulator (SERM). FDA Approved Indication(s) Osphena is indicated for the treatment of moderate to severe dyspareunia and vaginal dryness, symptoms of vulvar and vaginal atrophy, due to menopause. Policy/Criteria Provider must submit documentation (such as office chart notes, lab results or other clinical information) supporting that member has met all approval criteria. It is the policy of health plans affiliated with Centene Corporation® that Osphena is medically necessary when the following criteria are met: I. Initial Approval Criteria A. Dyspareunia or Vaginal Dryness (must meet all): 1. Diagnosis of dyspareunia or vaginal dryness due to menopause; 2. Age ≥ 18 years; 3. Failure of two vaginal lubricants or vaginal moisturizers at up to maximally indicated doses, unless contraindicated or clinically significant adverse effects are experienced; 4. Failure of ≥ 4 weeks of one vaginal estrogen at up to maximally indicated doses (e.g., estradiol vaginal cream, Premarin vaginal cream), unless contraindicated or clinically significant adverse effects are experienced; 5. Dose does not exceed 60 mg (1 tablet) per day. Approval duration: Medicaid/HIM – 12 months Commercial – Length of Benefit B. Other diagnoses/indications 1. Refer to the off-label use policy for the relevant line of business if diagnosis is NOT specifically listed under section III (Diagnoses/Indications for which coverage is NOT authorized): CP.CPA.09 for commercial, HIM.PHAR.21 for health insurance marketplace, and CP.PMN.53 for Medicaid.
    [Show full text]
  • HRT Communications 23.08.20191.Pdf
    DHSC - 23/8/2019 Hormone replacement therapy (HRT) supply issues The Department of Health and Social Care (DHSC) are aware of the ongoing manufacturing issues that have affected the supply of some hormone replacement therapy (HRT) products throughout 2019. Please see Table 1, which provides the latest update on the availability of all HRT products marketed in the UK and the known resupply date for products that are currently experiencing supply issues. This table also provides an update of all HRT preparations that remain available. Clinicians may be required to switch patients to alternative HRT products that contain the same active ingredients for a temporary period. Prescribing information regarding HRT equivalence to support local decision making is available through various sources such as the British National Formulary, Summary of Product Characteristics (SPC), The Monthly Index of Medical Specialities (MIMS), and other sources including local Medicines Information Centres. Clinicians are advised to work closely with community pharmacies to understand local availability of HRT products and use the table below to help make decision about appropriative HRT products for patients who are affected by the supply issues. DHSC will continue to provide updates on HRT availability in the monthly supply report, which is uploaded to the Specialist Pharmacist Services website. All registered user can access this update via this following link: https://www.sps.nhs.uk/articles/department-of-health-and- pharmaceutical-market-strategy-group-pmsg-supply-updates/ Please share this information with relevant networks locally including GP practices and community pharmacies. Table 1. HRT Availability Oestrogen Only Brand Strength Current Availability Anticipated resupply Ingredient (s) Manufacturer Oral preparations date Continued availability 1mg In stock to be confirmed.
    [Show full text]
  • OSPHENA) National Drug Monograph October 2015 VA Pharmacy Benefits Management Services, Medical Advisory Panel, and VISN Pharmacist Executives
    Ospemifene Monograph Ospemifene (OSPHENA) National Drug Monograph October 2015 VA Pharmacy Benefits Management Services, Medical Advisory Panel, and VISN Pharmacist Executives The purpose of VA PBM Services drug monographs is to provide a comprehensive drug review for making formulary decisions. Updates will be made when new clinical data warrant additional formulary discussion. Documents will be placed in the Archive section when the information is deemed to be no longer current. FDA Approval Information Description/Mechanism of Ospemifene is a selective estrogen receptor modulator (SERM) with agonist Action actions on vaginal tissue, the endometrium and bone. Antagonist actions suggest antitumor effects in experimental breast cancer models. Ospemifene is not interchangeable with other SERMs such as raloxifene or tamoxifen, nor they with it. Indication(s) Under Review in Ospemifene is an estrogen agonist/antagonist indicated for the treatment this document (may include of moderate to severe dyspareunia, a symptom of vulvar and vaginal off label) atrophy, due to menopause. Dosage Form(s) Under Tablet (oral), 60 mg Review REMS REMS X No REMS Postmarketing Requirements See Other Considerations for additional REMS information Pregnancy Rating X Executive Summary Efficacy After 12 weeks ospemifene reduced the symptom score of dyspareunia significantly more than placebo. Thirty-eight percent of postmenopausal women taking ospemifene reported no pain upon intercourse compared to 28% taking placebo. Ospemifene significantly improved the Maturation Index (composed of percent of vaginal parabasal and superficial cells, and vaginal pH) after 12 and 52 weeks of treatment. Vaginal dryness symptom scores improved significantly more with ospemifene than placebo. Use of vaginal lubricant decreased more in women taking ospemifene than placebo.
    [Show full text]
  • Reference List Abraham L, Pinkerton JV, Messig M, Ryan KA, Komm BS, Mirkin S
    SERM Education Project Reference List Abraham L, Pinkerton JV, Messig M, Ryan KA, Komm BS, Mirkin S. Menopause-specific quality of life across varying menopausal populations with conjugated estrogens/bazedoxifene. Maturitas. 2014;78(3):212-218. Archer DF, Carr BR, Pinkerton JV, Taylor HS, Constantine GD. Effects of ospemifene on the female reproductive and urinary tracts: translation from preclinical models into clinical evidence. Menopause. 2015;22(7):786-796. Archer DF, Lewis V, Carr BR, Olivier S, Pickar JH. Bazedoxifene/conjugated estrogens (BZA/CE): incidence of uterine bleeding in postmenopausal women. Fertil Steril. 2009;92(3):1039-1044. Archer DF. The gynecologic effects of lasofoxifene, an estrogen agonist/antagonist, in postmenopausal women. Menopause. 2011;18(1):6-7. Bachmann G, Bobula J, Mirkin S. Effects of bazedoxifene/conjugated estrogens on quality of life in postmentopausal women with symptoms of vulvar/vaginal atrophy. Climacteric. 2010;13(2):132-140. Bachmann G, Gass M, Kagan R, Moffett A, Barcomb L, Symons J. Lasofoxifene (LASO), a next generation selective estrogen response modulator (SERM) improves dyspareunia in postmenopausal women with vaginal atrophy (VA) [abstract]. Menopause. 2005;12(2):238. Bachmann G, Gass M, Moffett A, Portman D, Symons J. Lasofoxifene improves symptoms associated with vaginal atrophy [abstract]. Menopause. 2004;11(6):669. Abstract P-63. Bachmann GA, Komi JO; Ospemifene Study Group. Ospemifene effectively treats vulvovaginal atrophy in postmenopausal women: results from a pivotal phase 3 study. Menopause. 2010;17(3):480-486. Barrett-Connor E, Grady D, Sashegyi A, et al; MORE Investigators (Multiple Outcomes of Raloxifene Evaluation). Raloxifene and cardiovascular events in osteoporotic postmenopausal women: four-year results from the MORE (Multiple Outcomes of Raloxifene Evaluation) randomized trial.
    [Show full text]
  • OSPHENA Safely and Effectively
    HIGHLIGHTS OF PRESCRIBING INFORMATION Active DVT, pulmonary embolism (PE), or a history of these conditions These highlights do not include all the information needed to use (4, 5.1) OSPHENA safely and effectively. See full prescribing information for Active arterial thromboembolic disease (for example, stroke and OSPHENA. myocardial infarction [MI]), or a history of these conditions (4, 5.1) Known or suspected pregnancy (4, 8.1) OSPHENATM (ospemifene) tablets, for oral use Initial U.S. Approval: 2013 ---------------WARNINGS AND PRECAUTIONS------------ WARNING: ENDOMETRIAL CANCER AND CARDIOVASCULAR Venous Thromboembolism: Risk of DVT and pulmonary embolism DISORDERS (5.1) See full prescribing information for complete boxed warning. Known, suspected, or history of breast cancer (5.2) OSPHENA is an estrogen agonist/antagonist with tissue selective effects. In the endometrium, OSPHENA has estrogen agonistic effects. Severe Hepatic Impairment (5.3, 8.7, 12.3) There is an increased risk of endometrial cancer in a woman with a uterus who uses unopposed estrogens. Adding a progestin to estrogen -------------------ADVERSE REACTIONS---------------------- therapy reduces the risk of endometrial hyperplasia, which may be a precursor to endometrial cancer [see Warnings and Precautions (5.2)]. Adverse reactions (≥1 percent) include: hot flush, vaginal discharge, muscle spasms, genital discharge, hyperhidrosis. (6.1) Estrogen-alone therapy has an increased risk of stroke and deep vein thrombosis (DVT). OSPHENA 60 mg had cerebral thromboembolic To report SUSPECTED ADVERSE REACTIONS, contact Shionogi Inc. and hemorrhagic stroke incidence rates of 0.72 and 1.45 per thousand at 1-855-OSPHENA (1-855-677-4362) or FDA at 1-800-FDA-1088 or women, respectively vs.
    [Show full text]
  • MSAN(2020)67 – Hormone Replacement Therapy
    NHS Circular: MSAN (2020) 67 Chief Medical Officer Directorate Pharmacy and Medicines Division 23 July 2020 Medicine Supply Alert Notice Hormone Replacement Therapy (all formulations) Priority: Level 3* - update to MSAN (2020)3 Valid until: See table at Annex A Issue 1. The Chief Pharmaceutical Officer previously wrote in circular PCA(P)(2019)18 to community pharmacy contractors and NHS Boards regarding information on the availability of all Hormone Replacement Therapy (HRT) products marketed in the UK. This was updated in January 2020 by MSAN (2020)3. 2. This MSAN gives an update on the information provided in MSAN (2020)3, as issued by the UK Department of Health and Social Care Medicine Supply Team in July 2020. Advice and Actions 4. The table 1 attached at Annex A provides the latest update on the availability of all HRT products marketed in the UK and the known resupply date for products that are currently experiencing supply issues. The table also provides an update of all HRT preparations that remain available. 5. Clinicians may be required to switch patients to alternative HRT products that contain the same active ingredients for a temporary period. Prescribing information regarding HRT equivalence to support local decision making is available through various sources such as the British National Formulary, Summary of Product Characteristics (SPC), The Monthly Index of Medical Specialities (MIMS), and other sources including local Medicines Information Centres. Additional Information 6. Clinicians are advised to work closely with community pharmacies to understand local availability of HRT products and use the table below to help make decision about appropriative HRT products for patients who are affected by the supply issues.
    [Show full text]
  • Ospemifene for the Treatment of Dyspareunia Associated with Vulvar and Vaginal Atrophy: Potential Benefits in Bone and Breast
    International Journal of Women’s Health Dovepress open access to scientific and medical research Open Access Full Text Article REVIEW Ospemifene for the treatment of dyspareunia associated with vulvar and vaginal atrophy: potential benefits in bone and breast Lin H Soe Abstract: Ospemifene is a selective estrogen receptor modulator (SERM), or estrogen receptor Gregory T Wurz agonist/antagonist, that was recently approved by the US Food and Drug Administration for the Chiao-Jung Kao treatment of dyspareunia associated with vulvar and vaginal atrophy, a chronic condition that Michael W DeGregorio affects up to 60% of postmenopausal women. Ospemifene is the first and only nonestrogen com- pound approved for this indication. Compared with other approved SERMs, such as tamoxifen, Department of Internal Medicine, Division of Hematology and Oncology, toremifene, bazedoxifene, and raloxifene, the estrogen-like effects of ospemifene in the vaginal School of Medicine, University of epithelium are unique. This review first discusses the rationale for developing ospemifene, includ- California, Davis, Sacramento, CA, ing its mechanism of action, and then focuses on the clinical development of ospemifene for the USA treatment of dyspareunia associated with vulvar and vaginal atrophy. Included are discussions For personal use only. of the effects of ospemifene on the endometrium, serum lipids, coagulation markers, bone, and breast cancer. In conclusion, ospemifene is a SERM with a unique estrogen agonist/antagonist Video abstract tissue profile that was recently approved in the US for the treatment of dyspareunia associated with vulvar and vaginal atrophy in postmenopausal women. Ospemifene warrants further clinical investigation for the treatment and prevention of osteoporosis and breast cancer.
    [Show full text]
  • 2017 Hormone Therapy Position Statement of the North American Menopause Society
    Menopause: The Journal of The North American Menopause Society Vol. 24, No. 7, pp. 728-753 DOI: 10.1097/GME.0000000000000921 ß 2017 by The North American Menopause Society POSITION STATEMENT The 2017 hormone therapy position statement of The North American Menopause Society Abstract The 2017 Hormone Therapy Position Statement of The North American Menopause Society (NAMS) updates the 2012 Hormone Therapy Position Statement of The North American Menopause Society and identifies future research needs. An Advisory Panel of clinicians and researchers expert in the field of women’s health and menopause was recruited by NAMS to review the 2012 Position Statement, evaluate new literature, assess the evidence, and reach consensus on recommendations, using the level of evidence to identify the strength of recommendations and the quality of the evidence. The Panel’s recommendations were reviewed and approved by the NAMS Board of Trustees. Hormone therapy (HT) remains the most effective treatment for vasomotor symptoms (VMS) and the genito- urinary syndrome of menopause (GSM) and has been shown to prevent bone loss and fracture. The risks of HT differ depending on type, dose, duration of use, route of administration, timing of initiation, and whether a progestogen is used. Treatment should be individualized to identify the most appropriate HT type, dose, formulation, route of administration, and duration of use, using the best available evidence to maximize benefits and minimize risks, with periodic reevaluation of the benefits and risks of continuing or discontinuing HT. For women aged younger than 60 years or who are within 10 years of menopause onset and have no contraindications, the benefit-risk ratio is most favorable for treatment of bothersome VMS and for those at elevated risk for bone loss or fracture.
    [Show full text]
  • Senshio, INN-Ospemifene
    ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions. See section 4.8 for how to report adverse reactions. 1. NAME OF THE MEDICINAL PRODUCT Senshio 60 mg film-coated tablets 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each film-coated tablet contains 60 mg ospemifene. Excipient with known effect Each film-coated tablet contains 1.82 mg lactose as monohydrate. For the full list of excipients, see section 6.1. 3. PHARMACEUTICAL FORM Film-coated tablet (tablet). Oval biconvex, white to off-white, film-coated tablets of dimensions 12 mm x 6.45 mm, debossed with “60” on one side. 4. CLINICAL PARTICULARS 4.1 Therapeutic indications Senshio is indicated for the treatment of moderate to severe symptomatic vulvar and vaginal atrophy (VVA) in post-menopausal women who are not candidates for local vaginal oestrogen therapy. 4.2 Posology and method of administration Posology The recommended dose is one 60 mg tablet once daily with food taken at the same time each day. If a dose is missed it should be taken with food as soon as the patient remembers. A double dose should not be taken in the same day. Special populations Elderly (>65 years old) No dose adjustment is necessary in patients above the age of 65 years (see section 5.2). Renal impairment No dose adjustment is necessary for patients with mild, moderate or severe renal impairment (see section 5.2). 2 Hepatic impairment No dose adjustment is necessary for patients with mild to moderate hepatic impairment.
    [Show full text]